Key result
Familial hypercholesterolemia remains an underdiagnosed and undertreated genetic disease globally, with an estimated heterozygous prevalence of approximately 1 in 300 individuals.
Answers are grounded in this paper and cite their sources.
This editorial highlights recent advances in the genetics, screening, and management of familial hypercholesterolemia, emphasizing the need for early diagnosis and treatment to prevent cardiovascular disease.
The second volume of Research Topic "Genetics of Familial hypercholesterolemia: New Insight-Volume II" attracted nearly 100 authors from 16 countries to publish their research articles and again we achieved our goal of bringing together researches of familial hypercholesterolemia (FH) worldwide and to increase FH related awareness of genetics, diagnostics, and risk factors. In addition, Research Topic like future therapies for the treatment of homozygous form of FH (HoFH) gene therapy are discussed in this Research Topic (Li and Wu).
No takes yet. Share an insight, caveat, or question.
Vuorio et al. (2022) conducted an editorial in Familial hypercholesterolemia. Familial hypercholesterolemia remains an underdiagnosed and undertreated genetic disease globally, with an estimated heterozygous prevalence of approximately 1 in 300 individuals.
Synapse has enriched 10 related papers. Consider them for comparative context: